A Study to Determine the Efficacy and Safety of Halobetasol Propionate Lotion 0.05% in Subjects With Plaque Psoriasis

NCT01610596 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

72

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriasis
Plaque Psoriasis

Interventions

DRUG: Halobetasol Propionate Lotion 0.05%
DRUG: Placebo

Sponsor

Therapeutics, Inc.